首页> 外文OA文献 >Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the milan criteria
【2h】

Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the milan criteria

机译:在某些经过积极治疗且超过米兰标准的HCC患者中进行肝移植的意向分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract: This prospective study analyzed the dropout probability and intention-to-treat survival rates of patients with hepatocellular carcinoma (HCC) selected and treated according to our policy before liver transplantation (LT), with particular attention to those exceeding the Milan criteria. Exclusion criteria for LT were macroscopic vascular invasion, metastases, and poorly differentiated disease at percutaneous biopsy. A specific multi-modal adjuvant algorithm was used to treat HCC before LT. A total of 100 HCC patients were listed for LT: 40 exceeded the Milan criteria in terms of nodule size and number (MILAN OUT) either at listing or in list, while 60 patients continued to meet the criteria (MILAN IN). The Milan criteria did not prove to be a significant predictor of dropout probability or survival rates using Cox's analysis. Cumulative dropout probability at 6 and 12 months was 0% and 4% for MILAN OUT, and 6% and 11% for MILAN IN. The intention-to-treat survival rates at 1 and 3 years were 95% and 85% in MILAN OUT, and 84% and 69% in MILAN IN. None of the 68 transplanted patients had recurrent HCC after a median 16-month follow-up (0-69 months). In conclusion, LT may be effective for selected, aggressively-treated HCC patients exceeding the Milan criteria.
机译:摘要:这项前瞻性研究分析了根据我们的政策在肝移植(LT)之前选择和治疗的肝细胞癌(HCC)患者的辍学概率和意向治疗生存率,尤其要注意那些超出米兰标准的患者。 LT的排除标准为肉眼可见的血管浸润,转移和经皮穿刺活检时低分化疾病。一种特殊的多模式佐剂算法被用来治疗肝癌前LT。总共列出了100例HCC肝癌患者:其中有40例在结节或列表中结节大小和结节(MILAN OUT)超过了米兰标准,而60例继续符合该标准(MILAN IN)。根据考克斯的分析,米兰的标准并不能证明是辍学概率或存活率的重要预测指标。 MILAN OUT在6个月和12个月的累积辍学率分别为0%和4%,而MILAN IN分别为6%和11%。 MILAN OUT的1年和3年意向治疗生存率分别为95%和85%,MILAN IN的为84%和69%。在中位16个月的随访(0-69个月)后,这68例移植患者中均没有复发的HCC。总之,对于某些经过米兰治疗的积极治疗的HCC患者,LT可能有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号